In clinical trials, people who took lower doses of semaglutide lost less weight than those who took higher doses
Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis. Biological & Pharmaceutical Bulletin, vol
E-EL-R3007, Elabscience, Texas, USA), TGF-1 (Cat no
28-30 The GLP-1 receptor agonists available in Australia are dulaglutide, short-acting and modified-release exenatide and liraglutide
Individual results vary based on dose, adherence, starting weight, diet, activity, and individual biology
no clear plateau) Zepbound: ~20% to 22.5% (long-term studies) Glycemic Control (T2D): Retatrutide: HbA1c reduction up to ~2.0% (Phase III) Zepbound: Strong, well-established HbA1c reductions (~2.0% to 2.4%) across Phase III trials Durability of Effect: Retatrutide: Sustained weight loss with continued decline over time Zepbound: Durable, but tends to plateau earlier Safety & Tolerability: Retatrutide: Higher rates of GI side effects
